# Mechanism of Ocrelizumab in B-Cell Depletion ## Ocrelizumab targets CD20-positive B cells Ocrelizumab binds to CD20 on B cells and drives their depletion primarily through antibody-dependent cellular cytotoxicity mediated by monocytes via Fcγ receptor pathways, achieving rapid and sustained reduction of circulating B cells while also depleting CD20-positive T-cell subsets. # Abstract Ocrelizumab is a humanized anti-CD20 monoclonal antibody that targets the same CD20 epitope as rituximab but achieves B-cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) rather than complement-dependent cytotoxicity (CDC). The antibody was engineered with amino acid modifications to enhance binding to Fcγ receptor IIIa, resulting in two- to five-fold greater ADCC activity compared to rituximab. Monocytes serve as the dominant effector cells mediating B-cell depletion through FcγRI and FcγRIII-dependent pathways, achieving rapid onset within hours and near-complete depletion (>95%) of circulating B cells by week 2. However, depletion efficiency varies across anatomical compartments, with secondary lymphoid organs retaining resistant B-cell subpopulations and bone marrow showing the weakest reduction. Ocrelizumab also co-depletes CD20-positive T-cell subsets and novel dual-expressor lymphocytes expressing both T-cell and B-cell receptors. B-cell recovery begins in bone marrow and spleen before appearing in blood, with median time to repletion of 72 weeks. The phenotype of reconstituting B cells varies by immunological context: in settings with ongoing antigen stimulation, recovery is characterized by expansion of differentiated, myelin-reactive B cells, whereas absence of stimulation favors naive B-cell reconstitution. Treatment induces secondary immunological changes including increased BAFF levels and decreased sTACI, which may enhance regulatory plasma cell development and contribute to therapeutic efficacy. The ADCC-predominant mechanism provides more sustained depletion than CDC-predominant antibodies while potentially offering better tolerability. ## Methods We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. ## Data extraction We asked a large language model to extract each data column below from each paper. - **CD20 Targeting**: Extract details about how ocrelizumab targets CD20-positive B cells, including: - CD20 epitope specificity and binding characteristics - Binding affinity - Structure features affecting CD20 binding - Comparison of binding characteristics to other anti-CD20 antibodies - Dose-response relationships for CD20 binding - **Cytotoxic Mechanisms**: Extract all mechanisms by which ocrelizumab induces B-cell death after CD20 binding, including: - CDC activity and potency - ADCC activity and potency - Direct apoptosis induction - Other cytotoxic pathways - Quantitative comparisons of mechanism potency - Time course of cytotoxicity for each mechanism - Genetic or phenotypic factors affecting cytotoxic efficacy - **Depletion Patterns**: Extract detailed patterns of B-cell depletion caused by ocrelizumab, including: - B-cell subpopulations targeted - B-cell populations resistant to depletion - Anatomical compartments affected - Degree of depletion in each compartment - Co-depletion of CD20+ T cells or other immune cells - Factors influencing depletion efficiency - **Depletion Kinetics**: Extract timing and kinetics of B-cell depletion and recovery with ocrelizumab, including: - Time to initial B-cell depletion - Duration of maximal depletion - Recovery timeline for different B-cell populations - Recovery timeline for different anatomical compartments - Sequence of B-cell reconstitution - Phenotype of reconstituting B cells - **Molecular Determinants**: Extract molecular and structural features of ocrelizumab that influence its mechanism of action, including: - Antibody type - Heavy and light chain sequences - Fc region modifications or glycoengineering - Pharmacokinetic properties affecting mechanism - Dosing regimen and how it relates to mechanism optimization - Route of administration and mechanistic implications - **Comparative Mechanisms**: Extract direct comparisons of ocrelizumab’s mechanism to other anti-CD20 antibodies, including: - Head-to-head mechanistic comparisons - Relative potency differences in CDC vs ADCC mechanisms - Differences in B-cell depletion patterns between antibodies - Differences in depletion kinetics between antibodies - Unique mechanistic features of ocrelizumab vs competitors # Results ## Characteristics of Included Studies | Study | Full text retrieved? | Study focus | Key features | |-------|---------------------|-------------|---------------| | J. Uchida et al., 2004 | Yes | Mouse model of anti-CD20 therapy | Developed mouse anti-mouse CD20 antibody panel to study B-cell depletion mechanisms | | B. Cree et al., 2025 | Yes | Review of anti-CD20 antibody evolution | Comprehensive comparison of ocrelizumab, ofatumumab, ublituximab, and rituximab | | Pacheco-Fernández et al., 2018 | No | In vitro CDC comparison | Compared ofatumumab and ocrelizumab CDC activity using B-cell lines | | Samantha Ho et al., 2023 | Yes | B-cell regulating factors | Examined effects on BAFF-APRIL system over 2.5 years | | Schneider-Hohendorf et al., 2025 | No | B- and T-cell receptor repertoires | Analyzed adaptive immune changes in 35 MS patients on ocrelizumab | | Alice Willison et al., 2025 | Yes | Immune cell dynamics comparison | Compared ocrelizumab and ofatumumab with flow cytometry | | A. Bar-Or et al., 2021 | Yes | Clinical perspectives review | Detailed molecular and pharmacological attributes of four anti-CD20 antibodies | | Darius Häusler et al., 2018 | Yes | EAE model of B-cell recovery | Characterized B-cell depletion and reconstitution in murine MS model | | S. A. Kornilov et al., 2024 | No | Multi-omic characterization | Analyzed plasma proteome, metabolome, and lipidome changes in patients | | Prajita Paul et al., 2025 | No | Dual-expressor lymphocytes | Identified novel TCR/IgM dual-expressor cells susceptible to anti-CD20 therapy | ## Mechanisms of CD20 Targeting and B-cell Depletion ### CD20 Binding Characteristics Ocrelizumab is a humanized anti-CD20 monoclonal antibody that binds to the same epitope on the large extracellular loop of CD20 as rituximab. The antibody is classified as a type I anti-CD20 agent capable of crosslinking CD20 tetramers. Enhanced binding to low-affinity variants of Fcγ receptor IIIa distinguishes ocrelizumab from rituximab, contributing to its enhanced effector function. ### Cytotoxic Mechanisms Ocrelizumab depletes B cells through multiple cytotoxic pathways, with ADCC as the primary mechanism. The antibody exhibits two- to five-fold greater ADCC activity compared to rituximab, while demonstrating three- to five-fold lower CDC activity. Studies in mouse models demonstrate that B-cell depletion is completely dependent on effector cell Fc receptor expression. ## Patterns of B-cell Depletion ### B-cell Subpopulations Ocrelizumab targets CD20-positive B cells, resulting in significant reductions across multiple B-cell subsets including naive B cells, memory B cells, and transitional B cells. Plasma cells, which lack CD20 expression, remain resistant to depletion. ### Anatomical Compartments B-cell depletion occurs across multiple anatomical compartments but with varying efficiency. In blood, depletion is nearly complete, whereas B cells in lymphatic organs and the CNS are not depleted to the same extent. ## Kinetics of Depletion and Recovery ### Depletion Timeline The onset of B-cell depletion is rapid, occurring within 1 hour in mouse models, with CD19+ cell counts in humans almost completely depleted by week 2 after the first dose. ### Recovery Patterns In humans, B-cell levels increase to baseline or the lower limit of normal in 90% of patients within 2.5 years after the last infusion, with a median time to repletion of 72 weeks. ## Comparative Analysis with Other Anti-CD20 Antibodies ### Mechanistic Distinctions Ocrelizumab exhibits distinct mechanistic properties compared to other anti-CD20 antibodies. While all anti-CD20 agents induce both ADCC and CDC, their relative reliance on these pathways differs substantially. ## Secondary Effects on Immune Regulation ### BAFF-APRIL System Modulation Ocrelizumab treatment induces profound changes in the B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) system.